Versarien - Page 11

Versarien announced its financial results for the year ended on March 31. While revenues rose to £5.9 million (from £4.4 million in the previous year), the company's pre-tax losses also increased £2.2 million (from £1.8 million). At the end of the year Versarien had £1.4 million in cash and equivalents.

As part of its report, Versarien says that it entered into agreements to develop graphene enhanced polyetherketone type materials. Versarien also says that it shipped £100,000 worth of graphene to a European customer.

Versarien, the advanced materials group, has announced a fundraising of approximately £1 million (before expenses). The fundraising comprises an institutional placing by WH Ireland in conjunction with an offer via PrimaryBid.

The Company will use the proceeds of the fundraising to purchase capital equipment for its graphene businesses and for working capital.

Versarien, the advanced materials group that recently launched its new graphene brand called Nanene, has announced that it has signed heads of terms regarding a distribution agreement with Lansdowne Chemicals.

Lansdowne Chemicals, a member of the Overlack Group, is a chemical distribution, manufacturing and marketing company with two UK sites and operations in Europe, Asia and the USA. The agreement, which will be for an initial six months and thereafter terminable on three months notice, will help accelerate Versarien’s route to market for Nanene by enabling Lansdowne Chemicals to target customers which Versarien currently has no relationship with.

Versarien has launched its new graphene brand, called Nanene. It is reportedly manufactured using Versarien's mechanized exfoliation process, producing material less than five atoms thick.

Versarian said Nanene can be used in a variety of applications, including carbon fibre composites. "Having moved from the R&D phase and secured our first sizable order, we are pleased to launch our new graphene brand, Nanene," said Neill Ricketts, chief executive of Versarien. "We have already demonstrated that we can deliver high quality sizable graphene orders quickly and are confident of securing further significant orders in the coming months," he added.

Versarien has acquired a majority stake in Cambridge Graphene, a spin-out company from the University of Cambridge established in May 2014 to commercialize graphene inks. Versarien acquired a 85% stake for £180,000 - which values the entire Cambridge Graphene company at £200,000.

Cambridge Graphene develops inks based on graphene and related materials using processes developed at the Cambridge Graphene Center. The spin-out company has commercialized graphene inks for novel technology applications.

Versarien announced an agreement with Fern Plastic Products to manufacture injection moulded products using graphene-enhanced polyaryletherketone (PAEK) materials. The agreement with Fern Plastics follows the agreement with Scafell Organics announced earlier this month.

The plan is for Versarien to utilize Fern Plastics' manufacturing facilities and expertise to produce injection moulded products using graphene-enhanced PAEK materials produced through Versarien's collaboration with Scafell.

Versarien, the advanced materials group, has signed an agreement with polymer chemical producer Scafell Organics to develop graphene-enhanced polyaryletherketone materials (PAEKs). These materials are a family of semi-crystalline thermoplastics with high-temperature stability and high mechanical strength, used in the automotive and aerospace industries.

Versarien reportedly plans to utilize Scafell’s facilities and production expertise to produce graphene enhanced PAEK materials using Versarien supplied graphene nano platelets. It is hoped that these graphene enhanced materials will be available for sale by Versarien through its sales team as well as Scafell’s customers.

Versarien, the advanced materials group, announced the receipt of a significant graphene order for a carbon fibre composite related OEM application.

Versarien has received an order with a value of over £100,000 (around $124,900 USD) for graphene in the form of Few Layer Graphene Nano Platelets (GNPs) from a European commercial customer, in conjunction with the NGI. This graphene will be certified by the NGI and Versarien will be handling the dispersion of the GNPs into the resin to be used by the customer. The resin will be provided by the customer free of charge and will be returned to the customer in Europe once mixed with Versarien's GNPs.

Versarien recently announced the purchase of AAC Cyroma, a specialist plastic manufacturer, for about £1.4m to establish a dedicated graphene plastic manufacturing factory. Using Versarien's graphene manufacturing capabilities and AAC Cyroma's knowledge, plant and equipment, the acquisition will aim to enable the company to produce graphene-enhanced products, including automotive-related original equipment.

Versarien also bought The Breakfast Club 2000, a non-trading holding company which owns 85% AAC Cyroma's shares and the remaining 15% was bought from an individual, and together the shares will be admitted to AIM.

Versarien, an advanced materials group that creates innovative engineering solutions in a diverse range of industries, announced the participation of the Company's subsidiary, 2-DTech, in a new project funded by EPSRC (the UK's main agency for funding research in engineering and the physical sciences). The project 2D Materials for Next Generation Healthcare Technologies (2D-Health) started on October 1st and will utilize £5.2 million of funding over the next 5 years.

The project, in which Graphenea also recently announced its participation, is one of four major research grants awarded as part of the EPSRC Healthcare Technologies scheme, that will develop new technologies to address the health issues of an aging UK population. 2D-Health will aim to utilize the unique properties offered by graphene to develop innovative solutions for specific unmet clinical needs, particularly in wound care and management (relevant to diabetes), tissue rehabilitation by electrical stimulation (relevant to dementia), cell therapeutics (relevant to cardiovascular disease), and immunotherapeutics (relevant to cancer).